GlobalData on MSN11h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC
Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Rocket Report: A blue mood at Blue; Stoke Space fires a shot over the bow
Welcome to Edition 7.31 of the Rocket Report! The unfortunate news this week concerns layoffs. Blue Origin announced a 10 ...
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $28.80 Average Price Target from Brokerages
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports ...
How much does scientific progress cost? Without government dollars for research infrastructure, breakthroughs become improbable
It costs money to maintain the various facilities, utilities and personnel that allow scientists to conduct research in the ...
Scientific breakthroughs are hard without money for research infrastructure
Notably, indirect costs from grants do not cover the full cost of carrying out research at universities. In 2023, colleges and universities contributed approximately $27 billion of their own funding, ...
kalkinemedia3d
ARS Pharmaceuticals Navigating Growth and Institutional Dynamics in...
Highlights,ARS Pharmaceuticals (SPRY) has received favorable market target projections from research experts.,Significant ...
ARS Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $40 price target As the first and only approved ...